Physician profile
John Walter Mann
NPI 1487631602
$9,040.88
in general payments reported to CMS, 2019-2025
11 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,464 · 2020: $823 · 2021: $548 · 2022: $1,609 · 2023: $176 · 2024: $267 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medacta USA, INC. | $7,771.50 | 2019-2023 | Mpact |
| Stryker Corporation | $696.93 | 2020-2024 | Mako |
| Ferring Pharmaceuticals INC. | $177.11 | 2023-2025 | Euflexxa |
| Merz North America, INC. | $105.82 | 2022 | |
| Zimmer Biomet Holdings, INC. | $102.02 | 2019-2021 | |
| Depuy Synthes Sales INC. | $87.00 | 2024-2025 | Attune |
| Medical Device Business Services, INC. | $40.87 | 2025 | Velys |
| Heraeus Medical, LLC. | $19.30 | 2024 | |
| Si-Bone, INC. | $17.43 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $16.01 | 2025 | Zilretta |
| Heron Therapeutics, INC. | $6.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.